Merck's (MRK) Oncology Portfolio Gets Shot in the Arm with QLEX Nod

Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks in Goldman Sachs’ portfolio. On September 19, the company announced FDA approval for KEYTRUDA QLEX injection, the first subcutaneous version of its blockbuster cancer drug KEYTRUDA. Unlike the traditional intravenous (IV) form, QLEX can be administered subcutaneously (under the skin) in as little as one minute, providing patients and doctors with a faster and more convenient option.

This approval further strengthens Merck’s leadership in oncology, where KEYTRUDA is already a strong growth driver with approvals across 38 cancer indications. The new format is expected to expand adoption, particularly in community clinics and smaller practices where managing lengthy IV infusions can be difficult. It also enhances patient experience with both three-week and six-week dosing schedules.

Clinical results confirmed QLEX delivers safety and efficacy comparable to IV KEYTRUDA. With KEYTRUDA already generating multi-billion-dollar sales annually, the subcutaneous version provides Merck with a new lever to defend and grow its oncology franchise.

Merck & Co. Inc. (NYSE:MRK) is a global healthcare company that delivers medicines and vaccines, including those for oncology, infectious diseases, immunology, and cardiometabolic conditions.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Best Precious Metals Stocks to Buy Now and 11 Best Performing Data Center Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.